What are the latest treatments for rosacea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Latest Treatment of Rosacea

Topical Ivermectin 1% Cream is the Most Effective First-Line Treatment

For mild to moderate inflammatory rosacea (papules and pustules), topical ivermectin 1% cream once daily is the superior first-line choice, demonstrating 84.9% of patients achieving "clear" or "almost clear" ratings compared to 75.4% with metronidazole, with longer remission periods (115 days vs 85 days). 1, 2


Treatment Algorithm Based on Rosacea Phenotype

Mild Inflammatory Rosacea (Papules/Pustules)

  • Start with topical ivermectin 1% cream once daily as first-line monotherapy 1, 2

  • Alternative options include:

    • Topical azelaic acid 15% gel or foam (once to twice daily) - produces up to 51% success rate at 12 weeks 1, 2
    • Topical metronidazole 0.75% or 1.0% (once to twice daily) - produces up to 65% decrease in inflammatory lesion counts 1, 3
    • Encapsulated benzoyl peroxide 5% cream once daily - newest FDA-approved option showing rapid improvement by week 2 with sustained efficacy up to 52 weeks 1, 2
  • Expect clinical improvement within 3-4 weeks for most topical treatments, but continue for minimum 6-12 weeks to adequately assess efficacy 1, 2

Moderate to Severe Inflammatory Rosacea

  • Initiate combination therapy: topical ivermectin 1% cream PLUS oral doxycycline 40 mg modified-release daily for more rapid control 1, 2
  • Alternative combination: topical azelaic acid 15% gel/foam PLUS oral doxycycline 40 mg daily 1
  • Minocycline foam 1.5% is FDA-approved for moderate to severe disease, achieving 52% IGA success rates versus 43% with vehicle 1, 2

Persistent Facial Erythema (Redness/Flushing)

  • Topical brimonidine tartrate 0.33% gel once daily provides rapid vasoconstriction with maximal effects between 3-6 hours after application 1, 2
    • Caution: Paradoxical erythema occurs in 10-20% of patients 2, 4
  • Alternative: Topical oxymetazoline HCl 1% cream once daily with composite success rates of 12.3-14.8% at 12 hours 1, 4
  • Physical modalities like IPL (intense pulsed light) or PDL (pulsed dye laser) should be considered for persistent erythema and telangiectasias 1, 5

Refractory or Severe Disease

  • Encapsulated benzoyl peroxide 5% cream demonstrates rapid improvement by week 2 with progressive clinical improvement for up to 52 weeks, with 44-50% of patients achieving 2-grade improvement to clear or almost clear skin by week 12 1
  • The microencapsulated technology gradually releases the drug to minimize irritation, addressing a common reason for treatment failure 1

Critical Application Guidelines

When Using Multiple Topical Agents

  • Apply one agent in the morning and one in the evening to minimize potential irritation 1, 4
  • For example: ivermectin 1% cream in morning + azelaic acid 15% gel in evening 1

Treatment Duration and Maintenance

  • Minimum 6-12 weeks of continuous use is required before determining treatment success or failure 1
  • Without maintenance therapy, up to two-thirds of patients will relapse when treatment is discontinued 1, 2
  • Long-term maintenance with topical agents is essential to prevent relapses - use the minimum treatment necessary to maintain control 1, 2
  • Ivermectin provides more durable response with longer time until relapse (115 days) compared to metronidazole (85 days) 1, 2

Essential Adjunctive Measures

General Skincare (Non-Negotiable)

  • Sun protection with SPF 30+ daily 1, 2
  • Gentle cleansers and moisturizers 1, 2
  • Identify and avoid personal triggers including spicy foods, alcohol, and extreme temperatures 2, 4

Ocular Rosacea Management

  • Lid hygiene for mild cases 2
  • Oral doxycycline for moderate to severe ocular involvement 2

Common Pitfalls and How to Avoid Them

Adherence Issues

  • Up to 89% of patients who experience treatment-related adverse effects discontinue therapy within a month 1, 2
  • Encapsulated benzoyl peroxide 5% demonstrates excellent tolerability comparable to vehicle, addressing this major barrier 1
  • Ivermectin 1% cream is generally well-tolerated with once-daily application 1

Premature Discontinuation

  • Discontinuing therapy before 6-8 weeks prevents adequate assessment of efficacy 1
  • Many studies with durations under 8 weeks were deemed inadequate to demonstrate true treatment effects 1

Inadequate Treatment of Multiple Features

  • Multiple cutaneous features of rosacea may require simultaneous treatment with different agents 1, 2
  • For example: inflammatory lesions require anti-inflammatory topicals (ivermectin, azelaic acid), while persistent erythema requires vasoconstrictors (brimonidine, oxymetazoline) 1, 2

Ignoring Maintenance Therapy

  • Relapse rates are high without maintenance - continue topical therapy long-term even after achieving clear or almost clear status 1, 2, 4

Special Population: Breastfeeding

  • Topical azelaic acid 15% gel/foam, metronidazole 0.75-1%, and ivermectin 1% cream are safe options during breastfeeding 4
  • Oral doxycycline is explicitly contraindicated by the FDA in nursing women - avoid its use during breastfeeding 4
  • Topical brimonidine 0.33% gel and oxymetazoline HCl 1% cream may be used for persistent erythema 4

References

Guideline

First-Line Treatment for Rosacea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Facial Rosacea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Rosacea Treatment During Breastfeeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Rosacea management: A comprehensive review.

Journal of cosmetic dermatology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.